Type, timing, and risk factors associated with immune-related adverse event development in patients with advanced genitourinary cancers treated with immune checkpoint inhibitor.Qian Qin, Che‐Kai Tsao, George Mellgard et al.|Journal of Clinical Oncology|2020Cited by 2
Characterizing patterns of disease progression in patients with genitourinary cancers treated with immune checkpoint inhibitors.Vaibhav G. Patel, Che‐Kai Tsao, Suraj K. Jaladanki et al.|Journal of Clinical Oncology|2020Cited by 1